Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,618 across all filing types
Latest filing 2025-09-08 Investor Presentation
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Investor Presentation E&P Small Cap Healthcare Conference 18 pages 1.3MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation from a CEO at a healthcare conference, dated September 2025, focusing on clinical trial updates, drug development pipeline, financial highlights, shareholder information, and strategic outlook. It includes forward-looking statements, interim clinical data updates, market opportunity analysis, and next steps in clinical development. The content is typical of an investor presentation aimed at providing comprehensive information on company strategy, clinical progress, and financial positioning to investors and analysts. There is no indication that this is a formal regulatory filing like an annual or interim report, audit report, or earnings release. It is not a transcript of a call, nor a voting or dividend announcement. The length and detail confirm it is a full presentation document rather than a brief announcement or report publication notice.
2025-09-08 English
Letter to shareholders - path forward for amsulostat 3 pages 208.7KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 1 September 2025 from Syntara Limited, addressing shareholders about recent FDA guidance on the clinical development pathway for their drug candidate amsulostat. It discusses regulatory feedback, clinical trial plans, and strategic next steps, but does not contain financial statements, detailed financial performance data, or comprehensive management analysis. The document is a communication to shareholders providing an update on clinical development and regulatory strategy rather than a formal financial report or earnings release. It is not a transcript of a call, nor a notice of voting results or capital changes. The length (8342 characters) and content indicate it is a detailed announcement but not a full report like an Annual or Interim Report. Therefore, the best fitting category is a Regulatory Filing (RNS), as it is a general regulatory announcement and shareholder update that does not fit other specific categories.
2025-08-31 English
Application for quotation of securities - SNT 6 pages 18.4KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) announcement for the application for quotation of securities. It details the issuance and quotation of new securities resulting from the exercise of options or conversion of convertible securities. The document includes specifics such as the number of securities, issue date, and class of securities. This type of announcement is related to changes in the company's capital structure, specifically the issuance and quotation of new shares. It is not a financial report, earnings release, or management discussion, but rather a formal notification of a capital change event. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and content confirm it is a full announcement, not just a brief notice or report publication announcement.
2025-08-27 English
Preliminary Final Report 58 pages 3.9MB
Annual Report Classification · 100% confidence The document is titled 'Syntara Limited Appendix 4E Preliminary final report' and covers the financial year ended 30 June 2025. It includes detailed financial results, directors' report, auditor's report, consolidated financial statements, and other comprehensive financial information. The presence of a full directors' report, auditor's independence declaration, consolidated statements of profit or loss, financial position, changes in equity, cash flows, notes to financial statements, and an independent auditor's report indicates this is a comprehensive annual financial report. Appendix 4E is a regulatory filing used in Australia for preliminary final reports, which are typically preliminary annual reports. The document is 15,000 characters long, containing substantive financial data and analysis, not merely an announcement or certification. Therefore, this document fits the definition of an Annual Report (10-K equivalent).
2025-08-27 English
Annual Report to shareholders 56 pages 3.9MB
Annual Report Classification · 100% confidence The document is titled 'Syntara Limited Contents 30 June 2025' and includes detailed sections such as Corporate directory, Directors' report, Auditor's independence declaration, consolidated financial statements, notes to the financial statements, Directors' declaration, and Independent auditor's report. The presence of comprehensive financial statements and auditor's report indicates this is a full annual report. The document length is 15,000 characters, which is consistent with a full annual report rather than a brief announcement. The date 30 June 2025 corresponds to a fiscal year-end, further supporting this classification. Therefore, this document is the company's Annual Report (10-K equivalent).
2025-08-27 English
Appendix 4G Key to Disclosures 14 pages 427.6KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It is a form used to confirm compliance with corporate governance disclosure requirements and acts as a key to where governance disclosures can be found. The document explicitly states it is not a substitute for the corporate governance statement itself but a verification tool lodged alongside the annual report. It contains no financial statements or substantive financial data but rather governance compliance checklists and references to where the actual governance statements are located (e.g., URLs). The document length is 15,000 characters, but the content is primarily a regulatory compliance form related to governance disclosures, not a full report or detailed governance report. According to the classification rules, such a document is best classified as a Regulatory Filing (RNS) because it is a regulatory compliance announcement and does not contain the full governance report or financial data itself.
2025-08-27 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.